Julia Lenore Marcus, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 81 | 2024 | 17591 | 5.650 |
Why?
|
Anti-HIV Agents | 40 | 2024 | 4576 | 5.590 |
Why?
|
Homosexuality, Male | 37 | 2024 | 1344 | 3.860 |
Why?
|
Hepatitis C | 8 | 2021 | 1595 | 2.070 |
Why?
|
Acquired Immunodeficiency Syndrome | 7 | 2023 | 2203 | 1.830 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 3 | 2024 | 31 | 1.800 |
Why?
|
Sexually Transmitted Diseases | 9 | 2021 | 668 | 1.690 |
Why?
|
Gonorrhea | 10 | 2020 | 355 | 1.440 |
Why?
|
Chlamydia Infections | 10 | 2020 | 365 | 1.440 |
Why?
|
Sexual Behavior | 16 | 2024 | 2200 | 1.400 |
Why?
|
Antiviral Agents | 7 | 2021 | 3070 | 1.310 |
Why?
|
HIV | 9 | 2023 | 1597 | 1.310 |
Why?
|
Hepacivirus | 8 | 2021 | 1344 | 1.290 |
Why?
|
Adenine | 5 | 2020 | 995 | 1.230 |
Why?
|
Safe Sex | 2 | 2019 | 144 | 1.110 |
Why?
|
Fluorenes | 2 | 2018 | 160 | 1.110 |
Why?
|
Sexual Partners | 10 | 2024 | 807 | 1.080 |
Why?
|
California | 12 | 2021 | 1443 | 1.000 |
Why?
|
Anti-Retroviral Agents | 4 | 2024 | 1795 | 0.970 |
Why?
|
Delivery of Health Care, Integrated | 5 | 2022 | 954 | 0.970 |
Why?
|
Prescription Drugs | 2 | 2022 | 635 | 0.960 |
Why?
|
Insurance, Life | 1 | 2024 | 14 | 0.940 |
Why?
|
Insurance, Disability | 1 | 2024 | 26 | 0.920 |
Why?
|
Hepatitis C, Chronic | 3 | 2021 | 1033 | 0.880 |
Why?
|
Neisseria gonorrhoeae | 5 | 2017 | 249 | 0.840 |
Why?
|
Rectal Diseases | 4 | 2019 | 142 | 0.840 |
Why?
|
Contact Tracing | 5 | 2021 | 275 | 0.840 |
Why?
|
Benzimidazoles | 2 | 2018 | 864 | 0.830 |
Why?
|
Nonprescription Drugs | 1 | 2023 | 119 | 0.800 |
Why?
|
Doxycycline | 1 | 2024 | 349 | 0.800 |
Why?
|
Syphilis | 4 | 2019 | 243 | 0.780 |
Why?
|
Life Expectancy | 2 | 2020 | 1249 | 0.750 |
Why?
|
Unsafe Sex | 2 | 2021 | 239 | 0.750 |
Why?
|
Deoxycytidine | 3 | 2014 | 888 | 0.720 |
Why?
|
Condoms | 2 | 2021 | 338 | 0.710 |
Why?
|
San Francisco | 13 | 2020 | 166 | 0.700 |
Why?
|
Intrauterine Devices, Copper | 1 | 2020 | 30 | 0.690 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2020 | 30 | 0.680 |
Why?
|
Insurance, Health | 3 | 2020 | 2518 | 0.600 |
Why?
|
Epidemics | 2 | 2021 | 517 | 0.600 |
Why?
|
CD4 Lymphocyte Count | 5 | 2018 | 2598 | 0.590 |
Why?
|
Drug Costs | 2 | 2022 | 1198 | 0.560 |
Why?
|
Health Communication | 1 | 2020 | 216 | 0.540 |
Why?
|
Chlamydia | 2 | 2018 | 33 | 0.540 |
Why?
|
Humans | 113 | 2024 | 768970 | 0.540 |
Why?
|
Holistic Health | 1 | 2016 | 47 | 0.530 |
Why?
|
Common Variable Immunodeficiency | 1 | 2017 | 100 | 0.520 |
Why?
|
Health Services Accessibility | 4 | 2023 | 5522 | 0.510 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 135 | 0.500 |
Why?
|
Chemoprevention | 2 | 2015 | 326 | 0.490 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2024 | 4056 | 0.470 |
Why?
|
Primary Health Care | 6 | 2021 | 4748 | 0.470 |
Why?
|
Medication Adherence | 6 | 2021 | 2192 | 0.460 |
Why?
|
Male | 67 | 2024 | 365203 | 0.460 |
Why?
|
Viral Load | 3 | 2021 | 3398 | 0.450 |
Why?
|
Incidence | 16 | 2024 | 21547 | 0.440 |
Why?
|
Urethra | 3 | 2013 | 407 | 0.420 |
Why?
|
Pneumococcal Vaccines | 1 | 2016 | 414 | 0.410 |
Why?
|
Herpesvirus 2, Human | 1 | 2014 | 191 | 0.410 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 869 | 0.410 |
Why?
|
Chlamydia trachomatis | 4 | 2017 | 239 | 0.400 |
Why?
|
Sentinel Surveillance | 3 | 2013 | 292 | 0.400 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1673 | 0.390 |
Why?
|
Adult | 47 | 2024 | 223851 | 0.390 |
Why?
|
Pneumococcal Infections | 1 | 2016 | 529 | 0.380 |
Why?
|
Oropharynx | 2 | 2017 | 139 | 0.380 |
Why?
|
Urethritis | 1 | 2011 | 30 | 0.380 |
Why?
|
Ambulatory Care Facilities | 6 | 2018 | 941 | 0.370 |
Why?
|
Syphilis Serodiagnosis | 1 | 2011 | 37 | 0.370 |
Why?
|
United States | 20 | 2024 | 73186 | 0.360 |
Why?
|
Herpes Simplex | 1 | 2014 | 470 | 0.350 |
Why?
|
Language | 1 | 2020 | 1559 | 0.350 |
Why?
|
Middle Aged | 37 | 2024 | 223737 | 0.340 |
Why?
|
Proctitis | 1 | 2010 | 40 | 0.340 |
Why?
|
Communicable Diseases, Emerging | 1 | 2011 | 148 | 0.330 |
Why?
|
Mass Screening | 6 | 2020 | 5457 | 0.320 |
Why?
|
Pharynx | 1 | 2011 | 436 | 0.310 |
Why?
|
Risk Reduction Behavior | 4 | 2020 | 1119 | 0.300 |
Why?
|
Female | 43 | 2024 | 397515 | 0.300 |
Why?
|
Communication | 2 | 2021 | 3908 | 0.280 |
Why?
|
Alanine | 2 | 2020 | 614 | 0.280 |
Why?
|
Patient-Centered Care | 2 | 2021 | 1447 | 0.280 |
Why?
|
Health Promotion | 2 | 2016 | 2210 | 0.280 |
Why?
|
Rectum | 1 | 2011 | 900 | 0.270 |
Why?
|
Costs and Cost Analysis | 2 | 2022 | 1669 | 0.270 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2024 | 113 | 0.260 |
Why?
|
Primary Prevention | 1 | 2014 | 1187 | 0.260 |
Why?
|
Cohort Studies | 13 | 2023 | 41808 | 0.260 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7478 | 0.250 |
Why?
|
Acute Coronary Syndrome | 1 | 2018 | 2194 | 0.250 |
Why?
|
Pneumonia | 1 | 2017 | 2164 | 0.250 |
Why?
|
Patient Compliance | 2 | 2017 | 2701 | 0.240 |
Why?
|
Risk-Taking | 3 | 2021 | 1023 | 0.240 |
Why?
|
Young Adult | 18 | 2024 | 60131 | 0.240 |
Why?
|
Prostate-Specific Antigen | 1 | 2014 | 2487 | 0.230 |
Why?
|
Prevalence | 11 | 2020 | 15879 | 0.230 |
Why?
|
Patient Acceptance of Health Care | 4 | 2022 | 3235 | 0.200 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3421 | 0.200 |
Why?
|
Motivation | 2 | 2022 | 2025 | 0.200 |
Why?
|
Bisexuality | 1 | 2024 | 295 | 0.200 |
Why?
|
Orgasm | 1 | 2021 | 63 | 0.190 |
Why?
|
Neoplasms | 3 | 2021 | 22389 | 0.190 |
Why?
|
Georgia | 1 | 2021 | 186 | 0.180 |
Why?
|
Africa, Eastern | 1 | 2020 | 76 | 0.180 |
Why?
|
Child Abuse | 1 | 2009 | 1091 | 0.170 |
Why?
|
Interviews as Topic | 4 | 2019 | 2744 | 0.170 |
Why?
|
Levonorgestrel | 1 | 2020 | 80 | 0.170 |
Why?
|
Glycolipids | 1 | 2000 | 205 | 0.160 |
Why?
|
Antibiotic Prophylaxis | 1 | 2024 | 641 | 0.160 |
Why?
|
Awards and Prizes | 1 | 2023 | 365 | 0.160 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 151 | 0.160 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2019 | 52 | 0.160 |
Why?
|
Aged | 15 | 2021 | 171786 | 0.160 |
Why?
|
Hospitalization | 1 | 2018 | 10847 | 0.150 |
Why?
|
Risk | 3 | 2021 | 9621 | 0.150 |
Why?
|
Adolescent | 10 | 2024 | 89244 | 0.150 |
Why?
|
Kenya | 1 | 2020 | 758 | 0.150 |
Why?
|
Intention | 1 | 2020 | 348 | 0.140 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2016 | 1903 | 0.140 |
Why?
|
Models, Statistical | 2 | 2023 | 5110 | 0.140 |
Why?
|
Treatment Outcome | 6 | 2020 | 65480 | 0.140 |
Why?
|
Electronic Health Records | 4 | 2024 | 4879 | 0.140 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 473 | 0.130 |
Why?
|
Risk Factors | 11 | 2021 | 74976 | 0.130 |
Why?
|
Oligodendroglia | 1 | 2000 | 540 | 0.130 |
Why?
|
Myelin Sheath | 1 | 2000 | 653 | 0.130 |
Why?
|
Managed Care Programs | 1 | 2021 | 941 | 0.130 |
Why?
|
Viremia | 1 | 2019 | 725 | 0.130 |
Why?
|
Malnutrition | 1 | 2022 | 632 | 0.130 |
Why?
|
Uganda | 1 | 2020 | 1361 | 0.130 |
Why?
|
Cannabis | 1 | 2021 | 446 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 790 | 0.120 |
Why?
|
Vaccines, Conjugate | 1 | 2016 | 334 | 0.120 |
Why?
|
Health Personnel | 4 | 2023 | 3383 | 0.120 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7861 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 560 | 0.110 |
Why?
|
Recurrence | 3 | 2018 | 8513 | 0.110 |
Why?
|
Needle Sharing | 1 | 2013 | 22 | 0.110 |
Why?
|
Genotype | 2 | 2018 | 13048 | 0.110 |
Why?
|
Models, Biological | 1 | 2010 | 9499 | 0.110 |
Why?
|
Sex Distribution | 1 | 2018 | 2280 | 0.110 |
Why?
|
Health Maintenance Organizations | 1 | 2016 | 657 | 0.110 |
Why?
|
Pandemics | 3 | 2022 | 8749 | 0.110 |
Why?
|
Insurance Coverage | 1 | 2024 | 1946 | 0.100 |
Why?
|
Malaria | 1 | 2022 | 1249 | 0.100 |
Why?
|
Tobacco Use Disorder | 1 | 2018 | 708 | 0.100 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13594 | 0.100 |
Why?
|
Decision Support Systems, Clinical | 1 | 2022 | 1178 | 0.100 |
Why?
|
Retrospective Studies | 9 | 2023 | 81903 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4862 | 0.100 |
Why?
|
Stroke | 1 | 2014 | 9756 | 0.100 |
Why?
|
HIV-1 | 2 | 2020 | 6962 | 0.100 |
Why?
|
Health Policy | 1 | 2024 | 2700 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2014 | 11230 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2015 | 664 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2023 | 2063 | 0.090 |
Why?
|
Pharyngeal Diseases | 1 | 2012 | 134 | 0.090 |
Why?
|
Directive Counseling | 1 | 2012 | 171 | 0.090 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 764 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3324 | 0.090 |
Why?
|
Algorithms | 3 | 2023 | 14201 | 0.090 |
Why?
|
Renal Insufficiency | 1 | 2016 | 812 | 0.090 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2012 | 340 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 2018 | 781 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2018 | 6320 | 0.090 |
Why?
|
Medicare | 2 | 2019 | 6888 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 15661 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2018 | 22296 | 0.080 |
Why?
|
Tuberculosis | 1 | 2022 | 2029 | 0.080 |
Why?
|
Medicaid | 2 | 2023 | 2843 | 0.080 |
Why?
|
Heterosexuality | 1 | 2011 | 309 | 0.080 |
Why?
|
Confidence Intervals | 2 | 2011 | 2932 | 0.080 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2000 | 3612 | 0.080 |
Why?
|
Referral and Consultation | 2 | 2019 | 3628 | 0.080 |
Why?
|
Boston | 2 | 2019 | 9377 | 0.080 |
Why?
|
Alcoholism | 1 | 2019 | 1981 | 0.080 |
Why?
|
Transsexualism | 1 | 2012 | 210 | 0.080 |
Why?
|
Substance Abuse, Intravenous | 1 | 2013 | 530 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 590 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 2228 | 0.070 |
Why?
|
Family Planning Services | 1 | 2011 | 279 | 0.070 |
Why?
|
Cause of Death | 1 | 2018 | 3721 | 0.070 |
Why?
|
Domestic Violence | 1 | 2009 | 180 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39394 | 0.070 |
Why?
|
HIV Seropositivity | 2 | 2010 | 967 | 0.070 |
Why?
|
Survival Analysis | 2 | 2023 | 10115 | 0.070 |
Why?
|
Financing, Government | 1 | 2011 | 473 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2017 | 4423 | 0.070 |
Why?
|
Family Relations | 1 | 2009 | 318 | 0.070 |
Why?
|
Case Management | 1 | 2009 | 277 | 0.070 |
Why?
|
Community Health Centers | 2 | 2022 | 469 | 0.070 |
Why?
|
Galactosyltransferases | 2 | 2000 | 284 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2018 | 1886 | 0.070 |
Why?
|
Logistic Models | 2 | 2018 | 13318 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10592 | 0.060 |
Why?
|
Pilot Projects | 1 | 2019 | 8748 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9384 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12562 | 0.060 |
Why?
|
Confidentiality | 1 | 2009 | 606 | 0.060 |
Why?
|
Time Factors | 3 | 2019 | 40261 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6547 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3438 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2018 | 26395 | 0.060 |
Why?
|
Community Health Services | 1 | 2009 | 659 | 0.060 |
Why?
|
Massachusetts | 3 | 2022 | 8894 | 0.050 |
Why?
|
Climate Change | 1 | 2010 | 509 | 0.050 |
Why?
|
Ganglioside Galactosyltransferase | 2 | 2000 | 3 | 0.050 |
Why?
|
Population Surveillance | 1 | 2013 | 2597 | 0.050 |
Why?
|
Program Evaluation | 1 | 2011 | 2508 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2020 | 5375 | 0.050 |
Why?
|
Health Surveys | 2 | 2009 | 4055 | 0.050 |
Why?
|
Probability | 2 | 2023 | 2483 | 0.050 |
Why?
|
Alabama | 1 | 2022 | 112 | 0.050 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 38 | 0.050 |
Why?
|
Prescriptions | 1 | 2024 | 388 | 0.050 |
Why?
|
Ontario | 1 | 2022 | 403 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 24333 | 0.050 |
Why?
|
Age Distribution | 2 | 2021 | 2875 | 0.050 |
Why?
|
Galactolipids | 1 | 2000 | 4 | 0.040 |
Why?
|
Self Report | 1 | 2012 | 3773 | 0.040 |
Why?
|
Mice, Neurologic Mutants | 1 | 2000 | 107 | 0.040 |
Why?
|
Cultural Competency | 1 | 2023 | 303 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2018 | 5892 | 0.040 |
Why?
|
Myelin Proteins | 1 | 2000 | 212 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8231 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2019 | 59739 | 0.040 |
Why?
|
Education, Medical, Continuing | 1 | 2023 | 829 | 0.040 |
Why?
|
Policy | 1 | 2021 | 514 | 0.040 |
Why?
|
North America | 1 | 2021 | 1290 | 0.040 |
Why?
|
Qualitative Research | 2 | 2019 | 3143 | 0.030 |
Why?
|
Pregnancy | 2 | 2021 | 30265 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10400 | 0.030 |
Why?
|
Minority Groups | 1 | 2023 | 1216 | 0.030 |
Why?
|
Self Efficacy | 1 | 2020 | 643 | 0.030 |
Why?
|
Cell Count | 1 | 2000 | 1833 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2515 | 0.030 |
Why?
|
Aging | 1 | 2014 | 8745 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 1076 | 0.030 |
Why?
|
Postpartum Period | 1 | 2021 | 1198 | 0.030 |
Why?
|
Schools | 1 | 2023 | 1498 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2021 | 1360 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2019 | 878 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2022 | 2360 | 0.030 |
Why?
|
Perception | 1 | 2020 | 1209 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2015 | 11521 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21188 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2010 | 15471 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 2013 | 263 | 0.030 |
Why?
|
Genes | 1 | 1996 | 1824 | 0.030 |
Why?
|
Axons | 1 | 2000 | 1678 | 0.020 |
Why?
|
Spinal Cord | 1 | 2000 | 1813 | 0.020 |
Why?
|
Phylogeny | 1 | 2019 | 2843 | 0.020 |
Why?
|
RNA | 1 | 2000 | 2727 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 979 | 0.020 |
Why?
|
Mental Disorders | 1 | 2009 | 6876 | 0.020 |
Why?
|
Computer Simulation | 1 | 2023 | 6291 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2013 | 5544 | 0.020 |
Why?
|
Odds Ratio | 2 | 2011 | 9684 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3438 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1645 | 0.020 |
Why?
|
Cognition | 1 | 2024 | 7081 | 0.020 |
Why?
|
Child, Preschool | 1 | 2009 | 42683 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 1741 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2013 | 1063 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 1194 | 0.020 |
Why?
|
Public Policy | 1 | 2010 | 552 | 0.020 |
Why?
|
Decision Making | 1 | 2019 | 3953 | 0.020 |
Why?
|
Research Personnel | 1 | 2010 | 590 | 0.020 |
Why?
|
Politics | 1 | 2010 | 822 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2000 | 11684 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14794 | 0.010 |
Why?
|
Research | 1 | 2010 | 1981 | 0.010 |
Why?
|
Mice | 2 | 2000 | 82072 | 0.010 |
Why?
|
Women's Health | 1 | 2011 | 2081 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2009 | 1798 | 0.010 |
Why?
|
Child | 1 | 2009 | 80960 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2009 | 6236 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12467 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1996 | 421 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 54962 | 0.010 |
Why?
|
Glucuronosyltransferase | 1 | 1996 | 136 | 0.010 |
Why?
|
Public Health | 1 | 2009 | 2680 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30266 | 0.010 |
Why?
|
Databases, Factual | 1 | 2009 | 8094 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1996 | 2749 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1996 | 2179 | 0.010 |
Why?
|
Species Specificity | 1 | 1996 | 2417 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1996 | 4168 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15951 | 0.010 |
Why?
|
Animals | 2 | 2000 | 169335 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1996 | 2525 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 1996 | 4625 | 0.000 |
Why?
|
Base Sequence | 1 | 1996 | 12430 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1996 | 13427 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1996 | 17629 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1996 | 7609 | 0.000 |
Why?
|
Rats | 1 | 1996 | 23786 | 0.000 |
Why?
|